Last reviewed · How we verify
Baracle Tab.®
Baracle Tab. is a beta blocker used to treat hypertension and prevent myocardial infarction.
Baracle Tab. is a beta blocker used to treat hypertension and prevent myocardial infarction. Used for Hypertension, Prevention of myocardial infarction.
At a glance
| Generic name | Baracle Tab.® |
|---|---|
| Also known as | Prophylactic treatment group |
| Sponsor | Seoul St. Mary's Hospital |
| Drug class | beta blocker |
| Target | beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Beta blockers like Baracle Tab. work by blocking the effects of the hormone epinephrine, also known as adrenaline, and by slowing the heart rate and reducing its workload. This leads to a decrease in blood pressure and a reduction in the risk of heart attack.
Approved indications
- Hypertension
- Prevention of myocardial infarction
Common side effects
- Bradycardia
- Fatigue
- Dizziness
Key clinical trials
- Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation (NA)
- Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Baracle Tab.® CI brief — competitive landscape report
- Baracle Tab.® updates RSS · CI watch RSS
- Seoul St. Mary's Hospital portfolio CI